NCIC CLINICAL TRIALS GROUP

BRAIN DISEASE SITE COMMITTEE MEETING AGENDA - OPEN SESSIONS

Venue: Carlyle

Date: Saturday, May 3rd 2014 Time: 9:00 a.m. – 12:00 p.m.

Chair: Dr. Warren Mason

9:00 am **Welcome and Introductions**

COMPLETED STUDIES

9:05 am IND. 204: A Phase II Study of the Phosphatidylinositol-3-OH Kinase (PI3K) Inhibitor PX-866 in Recurrent Glioblastoma M.Pitz

9:10 am **CE5 (EORTC 22033-26033):** Primary Chemotherapy with Temozolomide *vs* Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic

1P Loss: A Phase III Study W. Mason

CE.5S: The Sociobehavioural Effects of Primary Chemotherapy with Temozolomide *vs* Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic

1P Loss: A Phase III Study

A. Leis

TRIALS CLOSED TO ACCRUAL

9:15 am **CE.6:** A Randomized Phase III Study of Temozolomide a Short-Course Radiation

versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed

Gliobalstoma Multiforme in Elderly Patients

J. Perry

ACTIVELY ACCRUING TRIALS

9:20 am **CEC.1 (EORTC 26053_22054)**: Phase III Trial of Concurrent and Adjuvant

Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma.

The CATNON Intergroup Trial

W. Mason

D. Roberge

9:25 am **CEC.3 (NCCTG N107C):** A Phase III Trial of Post-Surgical Stereotactic

Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for Resected

Metastatic Brain Disease

NEW TRIALS/CONCEPTS FOR DISCUSSION

9: 30 am (Alliance 071102) Randomized Trial of ABT-888 or Placebo in Combination

with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter

Hypermethylation P. Brown

PREVIOUSLY APPROVED/REVISED TRIALS

9:50 am **CEC.2 (Alliance N0577)** Phase III Intergroup Study of Temozolomide Alone

versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q

Co-deleted Anaplastic Glioma. The CODEL Intergroup Trial

W. Mason

10:00-10:15 **Coffee Break**

NEW TRIALS/CONCEPTS FOR DISCUSSION

10:15 am (Alliance 221208) Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for

Brain Metastases

C. Chung

10: 35 am A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of

Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus BBI608 *versus* Conventional Concurrent Chemoradiation and Adjuvant

Temozolomide In Patients With Newly Diagnosed Glioblastoma

D. Kerstein

11:05 am **(ECOG)** Phase III Non-Inferiority Trial Comparing Radiation with Concurrent

Temozolomide With or Without Six Months of Adjuvant Temozolomide in

Patients with Newly Diagnosed Glioblastoma

L. Kleinberg

11:25 am Glycemic Impact on Glioblastoma Outcomes (GIGO) Study

C. Chung

MISCELLANEOUS

11:45 am Terry Fox Research Institute (TRFI) Grant: Therapeutic Targeting of GBM

Project Status Report

D. Kaplan

11:55 am **Report from IND Committee**

M. Pitz

12:00 pm **Closing Remarks**